US-based Corvida Medical has launched a multi-centre research study to evaluate improvements that its Closed System Transfer Device (CSTD) technology could bring to the safe handling of hazardous drugs.

The study is funded by the National Cancer Institute (NCI) as part of a series of Small Business Innovation Research (SBIR) grants.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company is currently seeking study participants to join the country’s leading cancer centres in a one day evaluation of medical devices used to improve safe handling of hazardous drugs.

More than 5.5 million healthcare workers annually are at risk of exposure to hazardous pharmaceuticals during the preparation and delivery of chemotherapy.

"NIOSH defined a CSTD as a drug transfer device, which prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapour concentrations outside the system."

Studies showed exposure to hazardous drugs can cause serious health problems, according to Occupational Safety and Health Administration (OSHA), National Institute of Occupational Safety and Health (NIOSH) and Joint Commission.

NIOSH defined a CSTD as a drug transfer device, which prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapour concentrations outside the system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Corvida Medical president Kent Smith said: "The grants from the NCI will help us advance Corvida’s soon-to-be-launched family of Halo brand CSTD products.

"The NCI SBIR study is a significant effort by the company to get leading cancer institutions in the US to explore applications of Halo and to demonstrate forward movement in safe handling."

Corvida Medical addresses the problems inherent in current CSTDs and develops smarter, simpler solutions to improve safety, productivity and quality for providers and patients.